Literature DB >> 23021058

Direct immunofluorescence testing in the diagnosis of immunobullous disease, collagen vascular disease, and vascular injury syndromes.

Cynthia M Magro1, Jennifer Roberts-Barnes, A Neil Crowson.   

Abstract

Direct and indirect immunofluorescence (IF) plays a role in the evaluation of immunobullous diseases and their mimics, and in the investigation of vascular injury syndromes and autoimmune connective tissue disease (CTD). IF mapping may be an important adjunct in the assessment of congenital epidermolysis bullosa syndromes and in Alport disease, in which antibodies are directed at certain components of the basement membrane zone to assay for their deficiency. In many cases of immunobullous and autoimmune CTDs, correlation with direct IF results is useful and often decisive in lesional evaluation and thus in patient management.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23021058     DOI: 10.1016/j.det.2012.06.008

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  4 in total

Review 1.  The 2016 Bowman Lecture Conjunctival curses: scarring conjunctivitis 30 years on.

Authors:  J K Dart
Journal:  Eye (Lond)       Date:  2017-01-20       Impact factor: 3.775

2.  Advanced Diagnostic Techniques in Autoimmune Bullous Diseases.

Authors:  Anuradha Jindal; Raghavendra Rao; Balbir S Bhogal
Journal:  Indian J Dermatol       Date:  2017 May-Jun       Impact factor: 1.494

3.  Evaluation of Dermoscopic Patterns of Vesiculobullous Disorders.

Authors:  Namita D Narkhede; Balakrishna Nikham; Varsha Jamale; Asma Hussain; Mohan Kale
Journal:  Indian J Dermatol       Date:  2021 Jul-Aug       Impact factor: 1.494

4.  Purpura fulminans-like lesions in antiphospholipid syndrome with endothelial C3 deposition.

Authors:  Jorge Magdaleno-Tapial; Cristian Valenzuela-Oñate; Javier Pitarch-Fabregat; María Marín-Jiménez; Clara Molina Almela; Johana Isidora Gutiérrez-Salcedo; Javier Calvo-Catalá; José Luis Sánchez-Carazo; V Alegre-de Miquel
Journal:  JAAD Case Rep       Date:  2018-10-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.